Supplementary Figure S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Figure S1. Tumor volume in CD49d+ and CD49d− CLL during acalabrutinib treatment
Supplementary Figure S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. | Synapse